A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors

Trial Profile

A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tozuleristide (Primary)
  • Indications Brain cancer; CNS cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Blaze Bioscience
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 11 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top